Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures

Abstract

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

1 . A locally deliverable composition for inhibiting pain/inflammation and spasm, comprising a combination of ketoprofen and a calcium channel antagonist in a carrier, each of the ketoprofen and the calcium channel antagonist included in a therapeutically effective amount such that the combination inhibits pain/inflammation and spasm at a site of local delivery. 
     
     
         2 . The composition of  claim 1 , wherein the calcium channel antagonist comprises an L-type calcium channel antagonist. 
     
     
         3 . The method of  claim 2 , wherein the L-type calcium channel antagonist is selected from the group consisting of verapamil, diltiazem, bepridil, mibefradil, nifedipine, nicardipine, isradipine, amlodipine, felodipine, nisoldipine and nimodipine. 
     
     
         4 . The method of claim wherein the L-type calcium channel antagonist comprises a dihydropyridine. 
     
     
         5 . The composition of  claim 4 , wherein the L-type calcium channel antagonist is selected from the group consisting of nifedipine, nicardipine, isradipine, amlodipine, felodipine, nisoldipine and nimodipine. 
     
     
         6 . The method of  claim 5 , wherein the L-type calcium channel antagonist comprises nifedipine. 
     
     
         7 . The composition of  claim 5 , wherein the L-type calcium channel antagonist has an onset of action of less than or equal to 10 minutes. 
     
     
         8 . The composition of  claim 1 , wherein the calcium channel antagonist comprises nifedipine. 
     
     
         9 . The composition of  claim 8 , wherein ketoprofen and nifedipine are included in the composition in a ketoprofen:nifedipine molar ratio of from 10:1 to 1:10. 
     
     
         10 . The composition of  claim 9 , wherein ketoprofen and nifedipine are included in the composition in a ketoprofen:nifedipine molar ratio of from 4:1 to 1:1. 
     
     
         11 . The composition of  claim 10 , wherein ketoprofen and nifedipine are included in the composition in a ketoprofen:nifedipine molar ratio of 3:1. 
     
     
         12 . The composition of  claim 8 , wherein ketoprofen is included in the composition at a concentration of no more than 500,000 nanomolar and nifedipine is included in the composition at a concentration of no more than 200,000 nanomolar. 
     
     
         13 . The composition of  claim 12 , wherein ketoprofen is included in the composition at a concentration of no more than 300,000 nanomolar and nifedipine is included in the composition at a concentration of no more than 100,000 nanomolar. 
     
     
         14 . The composition of  claim 13 , wherein ketoprofen is included in the composition at a concentration of no more than 50,000 nanomolar and nifedipine is included in the composition at a concentration of no more than 25,000 nanomolar. 
     
     
         15 . The composition of  claim 1 , wherein ketoprofen is included in the composition at a concentration of no more than 500,000 nanomolar and the calcium channel antagonist is included in the composition at a concentration of no more than 200,000 nanomolar. 
     
     
         16 . The composition of  claim 15 , wherein ketoprofen is included in the composition at a concentration of no more than 300,000 nanomolar and the calcium channel antagonist is included in the composition at a concentration of no more than 100,000 nanomolar. 
     
     
         17 . The composition of  claim 16 , wherein ketoprofen is included in the composition at a concentration of no more than 50,000 nanomolar and the calcium channel antagonist is included in the composition at a concentration of no more than 25,000 nanomolar. 
     
     
         18 . The composition of  claim 1 , wherein ketoprofen comprises the S-(+)-enantiomer, dexketoprofen. 
     
     
         19 . The composition of  claim 1 , wherein the composition is coated onto an implantable device or medical instrument. 
     
     
         20 . The composition of  claim 1 , wherein the composition is impregnated into an implantable device or medical instrument. 
     
     
         21 - 54 . (canceled)